These data, together with modeling of the G863V mutation based on the crystal structure of human MTP, provide new insight into the molecular details of lipid transfer by MTP and suggest that selective inhibition of TG transfer by MTP may be a feasible therapeutic approach to treat dyslipidemia. The gene discussed is MTTP; the disease is metabolic syndrome.